Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,469.30 +21.43 (+0.39%) Dow
39,112.16 -299.05 (-0.76%) Nasdaq
17,717.65 +220.84 (+1.26%) Bitcoin USD
61,329.58 +182.39 (+0.30%) CMC Crypto 200
1,275.32 -8.46 (-0.66%)
HALO Jun 2024 25.000 call
| Previous close | 19.70 |
| Open | 19.70 |
| Bid | 24.70 |
| Ask | 29.00 |
| Strike | 25.00 |
| Expiry date | 2024-06-21 |
| Day's range | 19.70 - 19.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
PR NewswireHalozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of OCREVUS® (ocrelizumab) SC co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Simply Wall St.Halozyme Therapeutics (NASDAQ:HALO) shareholder returns have been stellar, earning 193% in 5 years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
- PR Newswire
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received U.S. Food and Drug Administration (FDA) approval for VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
